The U.S. cancer care delivery system is undergoing profound changes to better meet the needs of people with cancer, but persistent hurdles threaten to slow progress, according to ASCO's fourth annual State of Cancer Care in America report released March 22, 2017.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
On March 21, Lancet Public Health published a study on the 2003 global tobacco control treaty’s impact on the adoption of tobacco reduction measures around the world, which has led to a 2.5% reduction in global smoking rates. The treaty obligates the 180 countries committed to it to implement strong evidence-based policies. While the US did sign on in 2004, it has never ratified this treaty.
STAT – a national publication focused on health and medicine – published an op-ed by ASCO President Daniel F. Hayes, MD, FACP, FASCO, on the critical importance of providing robust funding for the National Institutes of Health (NIH). The op-ed responds to the Administration's "budget blueprint," which proposes at 20 percent cut to the NIH.
In a congressional briefing on Capitol Hill, ASCO presented the State of Cancer Care in America: 2017, which examines significant changes occurring in the cancer care delivery system.
QOPI Certification Program LLC (QCP), an affiliate of ASCO that runs the QOPI Certification Program™, and the Foundation for Excellence and Quality in Oncology (ECO), a nonprofit foundation in Spain, have launched an effort to expand the QOPI Certification Program to Spain. Through the collaboration between ECO and QCP, Spanish oncology practices will be able to apply for QOPI Certification.
On March 22, ASCO’s big data initiative, CancerLinQ®, and newest journal, JCO Clinical Cancer Informatics (JCO CCI), will be highlighted at the Cancer Informatics for Cancer Centers (CI4CC) 2017 Spring Symposium and Workshop. This year’s meeting takes a focus on the role of registries in the national cancer data ecosystem.
On March 15, the Campaign for Tobacco-Free Kids, American Academy of Pediatrics, American Cancer Society Cancer Action Network, American Heart Association, and American Lung Association issued a new report titled “The Flavor Trap: How Tobacco Companies Are Luring Kids with Candy-Flavored E-Cigarettes and Cigars.”
We soundly oppose President Trump’s budget outline, which would cut $6 billion from the National Institutes of Health (NIH). Reducing NIH’s funding by nearly 20 percent will devastate our nation’s already fragile federal research infrastructure and undercut a longstanding commitment to biomedical science that has fueled advances in cancer prevention, diagnosis, and treatment.
The Centers for Medicare & Medicaid Services has extended the data submission deadline for the Electronic Health Record (EHR) reporting mechanism of the 2016 Quality Reporting Document Architecture (QRDA) for the Physician Quality Reporting System (PQRS) program. Individual eligible professionals (EPs), PQRS group practices, qualified clinical data registries (QCDRs), and qualified EHR data submission vendors (DSVs) now have until Friday, March 31 at 8:00 p.m. Eastern Time to submit 2016 EHR data via QRDA.
On March 14, the Spring Round for ASCO’s Quality Oncology Practice Initiative (QOPI®) opened for reporting; it will close on May 9 at 5 PM (EDT).
On March 14, 2017, The U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA®, Merck and Co., Inc.) for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or those who have relapsed after three or more prior lines of therapy.
On March 8, ASCO held a workshop on streamlining adverse events (AE) reporting for cancer clinical trials. Led by ASCO Past President Julie M. Vose, MD, MBA, FASCO, and ASCO President Daniel F. Hayes, MD, FACP, FASCO, the workshop focused on developing a roadmap for making AE reporting as meaningful and informative as possible and overcoming current issues with the reporting process.
On March 13, 2017, the U.S. Food and Drug Administration approved ribociclib (KISQALI®, Novartis Pharmaceuticals Corp.), a cyclin-dependent kinase 4/6 inhibitor, in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
“ASCO congratulates Seema Verma for her confirmation as Administrator of the Centers for Medicare & Medicaid Services (CMS). Administrator Verma is now in a key position to lead the agency during the next phase of healthcare reform in the United States, and to help ensure that millions of Medicare and Medicaid beneficiaries with cancer have access to high-quality oncology care."